98%
921
2 minutes
20
Ovarian cancer (OV) is the most lethal gynecological malignancy in the world. At present, the effect of m7G modification-related genes on the development of ovarian cancer remains unclear. We performed consensus clustering of ovarian cancer samples based on the expression of 24 m7G modification-related genes, and obtained 2 subtypes. There were some differences in immune cell infiltration between the two subtypes. Furthermore, enrichment analysis showed that differential genes were mainly enriched in several pathways and biological processes, including positive translation regulation and TRAPP complex. Multivariate cox regression analysis confirmed two genes (DCP2 and NUDT16) related to prognosis for the construction of risk score prediction models. The risk map of survival status showed that the high-risk samples had a shorter survival time (p<0.05). Risk score was an independent prognostic factor for OV and correlated with immunotherapy response. We also performed network analysis for DCP2 and NUDT16. We further explored the effects of the genes on cellular function and prognosis. In conclusion, this study provided a new perspective for the development mechanism of ovarian cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390964 | PMC |
http://dx.doi.org/10.3389/fimmu.2025.1595618 | DOI Listing |
Oncogene
September 2025
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Resistance to platinum-based drugs and PARP inhibitors (PARPi) is the leading cause of treatment failure in epithelial ovarian cancer (EOC). This study aimed to identify resistance mechanisms shared by both. Using bioinformatic analyses, EOC tissues, primary tumor cells and organoids, and chemoresistant cell lines, we identified lymphoid enhancer-binding factor 1 (LEF1) as a candidate, whose expression was increased in both platinum-resistant and PARPi-resistant tumors.
View Article and Find Full Text PDFBull Cancer
September 2025
Département d'oncologie médicale, centre Léon-Bérard (CLB-UNICANCER), université Claude-Bernard (UCB Lyon 1), Lyon, France. Electronic address:
Granulosa cell tumors (GCTs) are rare ovarian neoplasms, accounting for 2-5% of all ovarian cancers. Two histological types have been described: juvenile (JGCT) and adult (AGCT), the latter accounting for around 95% of the GCTs. AGCTs are mostly diagnosed at an early stage and commonly have a good prognosis.
View Article and Find Full Text PDFJ Immunother Cancer
September 2025
Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA
Background: Tumor heterogeneity and antigen escape are mechanisms of resistance to chimeric antigen receptor (CAR)-T cell therapy, especially in solid tumors. Targeting multiple antigens with a unique CAR construct could be a strategy for a better tumor control than monospecific CAR-T cells on heterogeneous models. To overcome tumor heterogeneity, we targeted mesothelin (meso) and Mucin 16 (MUC16), two antigens commonly expressed in solid tumors, using a tandem CAR design.
View Article and Find Full Text PDFAdv Med Sci
September 2025
Department of Biology, Lund University, Lund, Sweden.
Purpose: Ovarian cancer ranks as a gynecological malignancy with poor prognosis, specifically if detected late. Primary treatment includes cytoreductive surgery and adjuvant chemotherapy with curative intent. Local anesthetics (LA) administered in the perioperative period may potentially impact patient outcome by several mechanisms.
View Article and Find Full Text PDFCancer Genet
September 2025
Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea. Electronic address:
Background: Homologous recombination deficiency (HRD)-related genetic mutations in ovarian high-grade serous carcinoma (HGSC) are known to be ethnic specific. Here, we assessed the diagnostic performance of HRD and its clinical implication in Korean HGSC patients using the SOPHiA DDM HRD Solution.
Methods: Sixty-three ovarian cancer (OC) patients were enrolled, including 53 with HGSC and 10 with other subtypes.